恒瑞医药：注射用瑞康曲妥珠单抗联合阿得贝利单抗注射液和化疗获FDA孤儿药资格认定

Core Viewpoint - Heng Rui Medicine's product, injection of Rukang Trastuzumab combined with Atezolizumab and chemotherapy for gastric cancer or gastroesophageal junction adenocarcinoma, has received orphan drug designation from the U.S. Food and Drug Administration (FDA) [1] Group 1 - The orphan drug designation is aimed at drugs used for the prevention, treatment, or diagnosis of rare diseases [1] - The company will have opportunities to benefit from U.S. policy support in product development, registration, and commercialization [1]